Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Catalent, Inc. Announces Fourth Quarter Fiscal Year 2022 Earnings Conference Webcast


Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies, as well as consumer health products, today announced that it will release financial results for the fourth quarter of fiscal year 2022 ended June 30, 2022, before the market open on Monday, August 29, 2022. The Company's management will host a webcast to discuss the results at 8:15 a.m. ET on the same day.

Catalent invites all interested parties to listen to the webcast, which will be accessible through Catalent's website at http://investor.catalent.com.

A supplemental slide presentation will also be available in the "Investors" section of Catalent's website prior to the start of the webcast. The webcast replay, along with the supplemental slides, will be available for 90 days in the "Investors" section at www.catalent.com.

About Catalent, Inc.

Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is the industry's preferred partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of nearly 7,000 products to over 1,000 customers annually. Catalent's expert workforce exceeds 19,000, including more than 2,500 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. For more information, visit www.catalent.com.

More products. Better treatments. Reliably supplied.tm


These press releases may also interest you

at 11:06
Venom and KuCoin Ventures forge strategic partnership
Venom, an innovative layer-0 and layer-1 blockchain network capable of hosting projects at massive scale, has continued to expand its offerings, this time forming a strategic partnership with KuCoin Ventures, the investment arm of KuCoin, a leading...

at 11:00
Cerebrum Tech Founder & Chairman R.Erdem Erkul, PhD, appointed as the Honorary Consul of the Republic of Korea in Sivas
The Chairperson of the Digital Technologies Business Council of the Foreign Economic Relations Board (DEIK) - Digital Technologies Business Council and the Founder of Cerebrum Tech, Recep Erdem Erkul, PhD, was appointed as the Honorary Consul of the...

at 10:56
Global Times: Culture enhances understanding between China and Hungary
In Budapest, capital of East European country Hungary, signs, characters and cultural elements of the far Asian country of China are easily spotted as the China Cultural Center in the city aims to help more Hungarian people learn about China and...

at 10:35
Transatlantic Bridge Awards Honor Amb. Wendy Sherman, U.S. Chamber CEO Suzanne Clark, Prof. Timothy Snyder
The Delegation of the European Union to the United States honored three Americans for their important contributions to the transatlantic relationship Thursday with the 2024 Transatlantic Bridge Awards. The ceremony at the residence of Belgian...

at 10:30
POET Announces Closing of Private Placement Financing for CAD$10 Million
POET Technologies Inc. ("POET" or the "Company") , the designer and developer of the POET Optical Interposertm, Photonic Integrated Circuits (PICs) and light sources for the data center, tele-communication and AI markets, announced the closing of its...

at 10:30
Vendor Neutral Archive (VNA) & PACS Market Worth $7.3 billion | MarketsandMarketstm
Vendor Neutral Archive (VNA) & PACS Market in terms of revenue was estimated to be worth $4.6 billion in 2024 and is poised to reach $7.3 billion by 2029, growing at a CAGR of 9.5% from 2024 to 2029 according to a new report by MarketsandMarketstm....

More news about Science and technology...


News published on and distributed by: